Literature DB >> 20308595

How I treat hemochromatosis.

Paul C Adams1, James C Barton.   

Abstract

Hemochromatosis is a common genetic disorder in which iron may progressively accumulate in the liver, heart, and other organs. The primary goal of therapy is iron depletion to normalize body iron stores and to prevent or decrease organ dysfunction. The primary therapy to normalize iron stores is phlebotomy. In this opinion article, we discuss the indications for and monitoring of phlebotomy therapy to achieve iron depletion, maintenance therapy, dietary and pharmacologic maneuvers that could reduce iron absorption, and the role of voluntary blood donation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308595     DOI: 10.1182/blood-2010-01-261875

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Dietary iron intake and serum ferritin concentration in 213 patients homozygous for the HFEC282Y hemochromatosis mutation.

Authors:  Victor R Gordeuk; Laura Lovato; James Barton; Mara Vitolins; Gordon McLaren; Ronald Acton; Christine McLaren; Emily Harris; Mark Speechley; John H Eckfeldt; Sharmin Diaz; Phyliss Sholinsky; Paul Adams
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

Review 2.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

3.  Insulin Resistance and Metabolic Syndrome: Clinical and Laboratory Associations in African Americans Without Diabetes in the Hemochromatosis and Iron Overload Screening Study.

Authors:  James C Barton; Jackson Clayborn Barton; Ronald T Acton
Journal:  Metab Syndr Relat Disord       Date:  2018-05-31       Impact factor: 1.894

4.  MRI-based R2* mapping in patients with suspected or known iron overload.

Authors:  Emre Aslan; Jack W Luo; An Lesage; Philippe Paquin; Milena Cerny; Anne Shu-Lei Chin; Damien Olivié; Guillaume Gilbert; Denis Soulières; An Tang
Journal:  Abdom Radiol (NY)       Date:  2021-01-02

5.  Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.

Authors:  Tatjana Sundic; Tor Hervig; Signe Hannisdal; Jörg Assmus; Rune J Ulvik; Richard W Olaussen; Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-10-23       Impact factor: 3.443

6.  BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice.

Authors:  Elena Corradini; Paul J Schmidt; Delphine Meynard; Cinzia Garuti; Giuliana Montosi; Shanzhuo Chen; Slobodan Vukicevic; Antonello Pietrangelo; Herbert Y Lin; Jodie L Babitt
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

7.  Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the hemochromatosis and iron overload screening study.

Authors:  Paul C Adams; Mark Speechley; James C Barton; Christine E McLaren; Gordon D McLaren; John H Eckfeldt
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

8.  Serum ferritin, insulin resistance, and metabolic syndrome: clinical and laboratory associations in 769 non-hispanic whites without diabetes mellitus in the HEIRS study.

Authors:  Ronald T Acton; J Clayborn Barton; James C Barton
Journal:  Metab Syndr Relat Disord       Date:  2014-11-25       Impact factor: 1.894

9.  Progesterone receptor membrane component-1 regulates hepcidin biosynthesis.

Authors:  Xiang Li; David K Rhee; Rajeev Malhotra; Claire Mayeur; Liam A Hurst; Emily Ager; Georgia Shelton; Yael Kramer; David McCulloh; David Keefe; Kenneth D Bloch; Donald B Bloch; Randall T Peterson
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

10.  GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotes.

Authors:  James C Barton; Wen-Pin Chen; Mary J Emond; Pradyumna D Phatak; V Nathan Subramaniam; Paul C Adams; Lyle C Gurrin; Gregory J Anderson; Grant A Ramm; Lawrie W Powell; Katrina J Allen; John D Phillips; Charles J Parker; Gordon D McLaren; Christine E McLaren
Journal:  Blood Cells Mol Dis       Date:  2016-11-12       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.